BD PharmingenTM PE-CyTM7 Mouse IgG1 kappa Isotype Control

Description

Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control. Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control. Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control. Show More Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control. Show More Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control. Ig isotype control for the expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 4 hours with PMA 5 ng/ml, Sigma and Ionomycin 500 ng, Sigma in the presence of Brefeldin A GolgiPlug, Cat. No. 555029 . Cells were harvested, fixed, permeabilized and stained with PE Mouse Anti-Human CD8 Cat. No. 555367 and either PE-Cy7 Mouse Anti-Human IFN-gamma Cat. No. 557643; left panel or PE-Cy7 Mouse IgG1 kappa Isotype Control Cat. No. 557646/565573/557872; right panel as a specificity control by using Pharmingens staining protocol. To demonstrate additional specificity of staining the binding of PE-Cy7 Mouse Anti-Human IFN-gamma was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabeled Purified Mouse Anti-Human IFN-gamma 5 mug, Cat. No. 554699; data not shown prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence and isotype control.